Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration
Opthea Limited ((ASX:OPT, NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce that the U.S. Food and Drug